KR850700212A - 서방성 약제학적 캼셀제 - Google Patents

서방성 약제학적 캼셀제

Info

Publication number
KR850700212A
KR850700212A KR1019850700316A KR850700316A KR850700212A KR 850700212 A KR850700212 A KR 850700212A KR 1019850700316 A KR1019850700316 A KR 1019850700316A KR 850700316 A KR850700316 A KR 850700316A KR 850700212 A KR850700212 A KR 850700212A
Authority
KR
South Korea
Prior art keywords
capsule
hydroxypropylmethylcellulose
content
amount
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019850700316A
Other languages
English (en)
Korean (ko)
Inventor
라주 칼리딘디 사냐시
Original Assignee
죠지 드모트
아메리칸 홈프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 죠지 드모트, 아메리칸 홈프로덕츠 코포레이션 filed Critical 죠지 드모트
Publication of KR850700212A publication Critical patent/KR850700212A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019850700316A 1984-03-21 1985-02-22 서방성 약제학적 캼셀제 Withdrawn KR850700212A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59173884A 1984-03-21 1984-03-21
US591738 1984-03-21
PCT/US1985/000300 WO1985004100A1 (en) 1984-03-21 1985-02-22 Sustained release pharmaceutical capsules

Publications (1)

Publication Number Publication Date
KR850700212A true KR850700212A (ko) 1985-12-26

Family

ID=24367713

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850700316A Withdrawn KR850700212A (ko) 1984-03-21 1985-02-22 서방성 약제학적 캼셀제

Country Status (13)

Country Link
EP (1) EP0156592A3 (OSRAM)
JP (1) JPS61501511A (OSRAM)
KR (1) KR850700212A (OSRAM)
AU (1) AU4064285A (OSRAM)
DK (1) DK529885A (OSRAM)
ES (1) ES8700935A1 (OSRAM)
FI (1) FI854573A7 (OSRAM)
GB (1) GB2157169A (OSRAM)
GR (1) GR850625B (OSRAM)
HU (1) HUT38262A (OSRAM)
PT (1) PT80124B (OSRAM)
WO (1) WO1985004100A1 (OSRAM)
ZA (1) ZA851891B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2176999B (en) * 1985-06-22 1989-07-12 Stanley Stewart Davis Sustained release medicament
HU197201B (en) * 1985-10-01 1989-03-28 Sandoz Ag Process for producing oral pharmaceutical compositions of controlled solubility of the active components
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
SI8710406B (sl) * 1987-03-11 1998-08-31 Lek Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
IT1222414B (it) * 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
KR20120118031A (ko) * 2010-02-12 2012-10-25 닛산 가가쿠 고교 가부시키 가이샤 서방성 제제
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
BR112015016322A8 (pt) * 2013-01-09 2018-01-23 Edgemont Pharmaceuticals Llc formulações de liberação controlada de lorazepam
KR20210052281A (ko) 2019-10-29 2021-05-10 신에쓰 가가꾸 고교 가부시끼가이샤 캡슐 충전용 조성물 및 이것을 사용한 캡슐 제제의 제조 방법 그리고 캡슐 제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3427378A (en) * 1965-02-12 1969-02-11 American Cyanamid Co Sustained release encapsulated formula
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.

Also Published As

Publication number Publication date
WO1985004100A1 (en) 1985-09-26
DK529885D0 (da) 1985-11-15
AU4064285A (en) 1985-10-11
EP0156592A2 (en) 1985-10-02
GB8506656D0 (en) 1985-04-17
ES8700935A1 (es) 1986-11-16
HUT38262A (en) 1986-05-28
GB2157169A (en) 1985-10-23
EP0156592A3 (en) 1987-03-11
FI854573L (fi) 1985-11-20
ES541394A0 (es) 1986-11-16
DK529885A (da) 1985-11-15
ZA851891B (en) 1986-10-29
PT80124B (en) 1986-11-14
FI854573A0 (fi) 1985-11-20
FI854573A7 (fi) 1985-11-20
JPS61501511A (ja) 1986-07-24
PT80124A (en) 1985-04-01
GR850625B (OSRAM) 1985-06-17

Similar Documents

Publication Publication Date Title
KR850700212A (ko) 서방성 약제학적 캼셀제
EA200200840A1 (ru) Устойчивые к порче композиции опиоидных агонистов для перорального введения
KR960021032A (ko) 연성 젤라틴 약제학적 용량형
EA200200126A1 (ru) Гидродинамически сбалансированная пероральная система доставки лекарства
SE8304393L (sv) Naproxen- och naproxennatriumtabletter av controlled release-typ
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
KR890004686A (ko) 서방성 에토돌락
KR890009376A (ko) 분무 건조된 이부프로펜
BE901073A (fr) Composition antidiuretique a usage oral.
ATE65023T1 (de) Pharmazeutische mittel.
EA200600884A1 (ru) Композиции комплексов экстроген-циклодекстрин
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
KR880009634A (ko) 슈도에페드린 브롬페니라민 요법의 개량
NZ337418A (en) Paracetamol composition with improved rate of absorption
KR960000217A (ko) L- 카르니틴염과 이를 함유한 조성물
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
KR910009715A (ko) 요오드 함량이 높은 비이온성 x-선 조영제
KR870002845A (ko) 식욕조절 및 위암억제용 조성물
KR880004801A (ko) 서방성 약학적 조성물
RU93004785A (ru) Твердые капсулы окфосфата цитарабина

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19851120

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid